29 Dokumente gefunden

Prostate Artery Embolization vs. Holmium Laser Enucleation of the Prostate : A Matched Pair Analysis of Functional Outcomes…

Background : This retrospective matched-pair analysis compared functional outcomes and complications of prostate artery embolization (PAE) using 250 µm microparticles and holmium laser enucleation of the prostate (HoLEP) in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia…
Basel: MDPI, 2025-12-16

Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer—A Comparative Multireader Multicase Accuracy…

Objectives: To evaluate the diagnostic accuracy of AI-assisted biparametric MRI (AI-bpMRI) in detecting prostate cancer (PCa) as a possible replacement for multiparametric MRI (mpMRI) depending on readers’ experience. Methods: This fully crossed, multireader multicase, single-centre, consecutive study…
Basel: MDPI, 2025-08-29

Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien–Dindo Classification:…

aus: Cancers
Simple Summary This study looked at the complications that can occur following nephrectomies for kidney cancer with and without a so-called tumor thrombus, a tumor that has spread into the large vein called the inferior vena cava. So far, insufficient data are available on this topic. We developed a…
Basel: MDPI, 2024-10-18

Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced…

aus: Cancers
Simple Summary: In this work, we evaluated the need for frequent laboratory assessments in patients with metastatic renal cell carcinoma treated with nivolumab and nivolumab+ipilimumab during the TITAN-RCC clinical trial. We analysed how often reached criteria for dose delay or permanent discontinuation…
Basel: MDPI, 2024-06-20

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated…

Data on the effects of prior cytoreductive nephrectomy (CN) in patients with renal cell carcinoma (RCC) with synchronous metastases (M1 disease) before immune checkpoint inhibitor (ICI) treatment are limited. In this post hoc analysis of treatment-naive patients with advanced RCC from the phase 3 JAVELIN…
Amsterdam [u.a.]: Elsevier BV, 2024-01

The Antithetic Roles of IQGAP2 and IQGAP3 in Cancers

aus: Cancers
Simple Summary The IQ motif-containing GTPase-activating protein family is comprised of three signal scaffolding proteins that regulate a variety of biological functions by aiding signal transduction in cells. IQGAPs induce numerous cancer-related processes, including proliferation, apoptosis, migration,…
Basel: MDPI, 2023-02-09

The role and signaling mechanism of IQGAP2 in the progression of bladder cancer

Die Progression des nicht-muskel-invasiven Harnblasenkarzinoms (NMIBC) zum muskel-invasiven Blasenkarzinom (MIBC) stellt eine Herausforderung in der Urologie dar. Unsere Kenntnisse der zugrunde liegenden molekularen Prozesse sind begrenzt. In einer Studie mit 8 Patienten wurden NMIBC und metachrone MIBC…

Identifikation eines Markersets zur nicht-invasiven Diagnostik des Urothelkarzinoms der Harnblase, basierend auf genomweiten…

Das Harnblasenkarzinom (BCA) zählt mit 573.000 Neuerkrankungen pro Jahr zu den zehn häufigsten Krebserkrankungen weltweit. Allein in Deutschland werden jährlich ca. 30.000 Fälle neu diagnostiziert. Dabei stellt das nicht-muskelinvasive Harnblasenkarzinom (NMIBC) mit 70 % die mit Abstand häufigste Manifestationsform…

Effektivität und Sicherheit der Prostataarterienembolisation bei benigner Prostatahyperplasie : systematische Übersichtsarbeit…

Mit zunehmendem Alter leiden immer mehr Männer unter einer benignen Prostatahyperplasie (BPH). Die Prostataarterienembolisation (PAE) ist eine relativ neue, interventionell-radiologische, minimal-invasive Methode zur Behandlung der BPH. Ziel dieser Arbeit war, die Effektivität und Sicherheit der PAE…

Reduced IQGAP2 Promotes Bladder Cancer through Regulation of MAPK/ERK Pathway and Cytokines

The progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is a major challenge in urologic oncology. However, understanding of the molecular processes remains limited. The dysregulation of IQGAP2 is becoming increasingly evident in most tumor entities, and…
Basel: Molecular Diversity Preservation International, 2022-11-04

Recurrent Disseminated Intravascular Coagulation in Metastatic Castration-Resistant Prostate Cancer : A Case Report

Disseminated intravascular coagulation (DIC) is a systemic disease characterized by simultaneous thrombosis, bleeding, and partially excessive fibrinolysis. Systemic shock, trauma, bacterial toxins, and procoagulants-expressing solid and hematologic malignancies are common causes of this life-threatening…
Basel: MDPI, 2022-09-28

Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage

Results of three randomized clinical trials (RCTs) comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) of prostate carcinoma and a subsequent meta-analysis of the individual patient data from these RCTs were recently published. The results suggest that early eSRT is as effective…
Basel: MDPI, 2022-09-12

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma

aus: Cancers
Simple Summary Today, most patients with metastatic renal cancer receive systemic treatment with so-called immune-checkpoint inhibitors that shall activate a patient’s immune system. For patients without prior therapy, these therapeutic agents are combined with a second immunotherapeutic drug or with…
Basel: MDPI, 2022-09-08

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Background CheckMate 9KD ( NCT03338790 ) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucaparib.…
London: BMJ Publishing Group Ltd, 2022-08-17

The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer…

aus: Oncogene
Castration-resistant prostate cancer (CRPC) is an aggressive lethal form of prostate cancer (PCa). Atraric acid (AA) not only inhibits the wild-type androgen receptor (AR) but also those AR mutants that confer therapy resistance to other clinically used AR antagonists, indicating a different mode of…
London: Nature Publishing Group UK, 2022-06-03

Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells

Bladder cancer (BC) is characterised by a high recurrence and progression rate. However, the molecular mechanisms of BC progression remain poorly understood. BCL9L, a coactivator of β-catenin was mutated in the 5′ and 3′ untranslated regions (UTRs). We assessed the influence of UTRs mutations on BCL9L…
Basel: Molecular Diversity Preservation International, 2022-05-10

iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma : a…

Purpose: Therapy decision for patients with metastatic renal cell carcinoma (mRCC) is highly dependent on disease monitoring based on radiological reports. The purpose of the study was to compare non-standardized, common practice free text reporting (FTR) on disease response with reporting based on response…
Berlin: Springer, 2022-04-14

The androgen receptor—lncRNA SAT1- AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells

aus: Oncogene
The bipolar androgen therapy (BAT) to treat prostate cancer (PCa) includes cycles of supraphysiological androgen levels (SAL) under androgen-deprivation therapy (ADT). We showed previously that SAL induces cellular senescence in androgen-sensitive PCa cells and in ex vivo-treated patient PCa tumor samples.…
London: Nature Publishing Group UK, 2022-02-11

Analysis of the tumour-associated genes BCL9L and SLC35F2 in the progression of bladder cancer

The molecular mechanisms of progression remain poorly understood. From DNA sequencing analysis of non-muscle invasive (NMIBC) and corresponding muscle-invasive bladder cancer (MIBC) patients, the solute carrier family 35 member F2 (SLC35F2) and B-Cell Lymphoma 9-Like (BCL9L) were exclusively mutated…

Risk stratification and treatment algorithm of metastatic renal cell carcinoma

Systemic therapy for metastatic renal cell carcinoma has continuously evolved over the last two decades. Significant improvements in overall survival and quality of life of patients with advanced disease have been observed. With the approval of combination therapies with PD(L)-1 immune checkpoint inhibitors…
Basel: MDPI, 2021-11-16